Cargando…

New Immunosuppressive Therapies in Uveitis Treatment

Uveitis is an inflammatory process that initially starts in the uvea, but can also affect other adjacent eye structures, and is currently the fourth cause of blindness in developed countries. Corticoids are probably the most widespread treatment, but resorting to other immunosuppressive treatments i...

Descripción completa

Detalles Bibliográficos
Autores principales: Mérida, Salvador, Palacios, Elena, Navea, Amparo, Bosch-Morell, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581271/
https://www.ncbi.nlm.nih.gov/pubmed/26270662
http://dx.doi.org/10.3390/ijms160818778
_version_ 1782391532648660992
author Mérida, Salvador
Palacios, Elena
Navea, Amparo
Bosch-Morell, Francisco
author_facet Mérida, Salvador
Palacios, Elena
Navea, Amparo
Bosch-Morell, Francisco
author_sort Mérida, Salvador
collection PubMed
description Uveitis is an inflammatory process that initially starts in the uvea, but can also affect other adjacent eye structures, and is currently the fourth cause of blindness in developed countries. Corticoids are probably the most widespread treatment, but resorting to other immunosuppressive treatments is a frequent practice. Since the implication of different cytokines in uveitis has been well demonstrated, the majority of recent treatments for this disease include inhibitors or antibodies against these. Nevertheless, adequate treatment for each uveitis type entails a difficult therapeutic decision as no clear recommendations are found in the literature, despite the few protocolized clinical assays and many case-control studies done. This review aims to present, in order, the mechanisms and main indications of the most modern immunosuppressive drugs against cytokines.
format Online
Article
Text
id pubmed-4581271
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-45812712015-09-28 New Immunosuppressive Therapies in Uveitis Treatment Mérida, Salvador Palacios, Elena Navea, Amparo Bosch-Morell, Francisco Int J Mol Sci Review Uveitis is an inflammatory process that initially starts in the uvea, but can also affect other adjacent eye structures, and is currently the fourth cause of blindness in developed countries. Corticoids are probably the most widespread treatment, but resorting to other immunosuppressive treatments is a frequent practice. Since the implication of different cytokines in uveitis has been well demonstrated, the majority of recent treatments for this disease include inhibitors or antibodies against these. Nevertheless, adequate treatment for each uveitis type entails a difficult therapeutic decision as no clear recommendations are found in the literature, despite the few protocolized clinical assays and many case-control studies done. This review aims to present, in order, the mechanisms and main indications of the most modern immunosuppressive drugs against cytokines. MDPI 2015-08-11 /pmc/articles/PMC4581271/ /pubmed/26270662 http://dx.doi.org/10.3390/ijms160818778 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mérida, Salvador
Palacios, Elena
Navea, Amparo
Bosch-Morell, Francisco
New Immunosuppressive Therapies in Uveitis Treatment
title New Immunosuppressive Therapies in Uveitis Treatment
title_full New Immunosuppressive Therapies in Uveitis Treatment
title_fullStr New Immunosuppressive Therapies in Uveitis Treatment
title_full_unstemmed New Immunosuppressive Therapies in Uveitis Treatment
title_short New Immunosuppressive Therapies in Uveitis Treatment
title_sort new immunosuppressive therapies in uveitis treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581271/
https://www.ncbi.nlm.nih.gov/pubmed/26270662
http://dx.doi.org/10.3390/ijms160818778
work_keys_str_mv AT meridasalvador newimmunosuppressivetherapiesinuveitistreatment
AT palacioselena newimmunosuppressivetherapiesinuveitistreatment
AT naveaamparo newimmunosuppressivetherapiesinuveitistreatment
AT boschmorellfrancisco newimmunosuppressivetherapiesinuveitistreatment